MedPath
Found 288 clinical trials|View Analysis
Sort by:

Renal Resistive Index as an Indicator of Lupus Nephritis Severity and Systemic Lupus Activity

Not Applicable
Completed
Conditions
Systemic Lupus Erthematosus
Lupus Glomerulonephritis
Lupus Flare
First Posted Date
2025-01-03
Last Posted Date
2025-01-03
Lead Sponsor
Kasr El Aini Hospital
Target Recruit Count
75
Registration Number
NCT06757725
Locations
🇪🇬

Cairo University Hospitals, Cairo, Egypt

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients with Refractory Systemic Lupus Erythematosus (GALLOP)

Phase 1
Not yet recruiting
Conditions
Systemic Lupus Erythematosus
Lupus
Lupus Erythematosus
Lupus Nephritis
Interventions
First Posted Date
2024-12-31
Last Posted Date
2024-12-31
Lead Sponsor
Caribou Biosciences, Inc.
Target Recruit Count
20
Registration Number
NCT06752876

Phase Ib/IIa Study for IPG11406 in Patients with Lupus Nephritis

Phase 1
Not yet recruiting
Conditions
Lupus Nephritis
Interventions
Drug: IPG11406
First Posted Date
2024-12-05
Last Posted Date
2024-12-05
Lead Sponsor
Nanjing Immunophage Biotech Co., Ltd
Target Recruit Count
36
Registration Number
NCT06717815
Locations
🇨🇳

Nanjing DrumTower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China

Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)

Phase 3
Not yet recruiting
Conditions
Lupus Nephritis
Interventions
First Posted Date
2024-12-02
Last Posted Date
2024-12-02
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
316
Registration Number
NCT06711887

US Zamto-cel Autoimmune Diseases

Phase 1
Not yet recruiting
Conditions
Lupus Nephritis
Systemic Lupus Erythematosus
Systemic Sclerosis (SSc)
Diffuse Cutaneous Systemic Sclerosis
Interventions
Biological: zamtocabtagene autoleucel
Drug: Cyclophosphamide
Drug: Fludarabine
First Posted Date
2024-11-27
Last Posted Date
2024-11-27
Lead Sponsor
Miltenyi Biomedicine GmbH
Target Recruit Count
48
Registration Number
NCT06708845

High Quality Evidence of Guangzhou Lupus Nephritis Cohort (HOPE Cohort)

Recruiting
Conditions
Lupus Nephritis (LN)
First Posted Date
2024-11-11
Last Posted Date
2024-11-11
Lead Sponsor
First Affiliated Hospital, Sun Yat-Sen University
Target Recruit Count
5000
Registration Number
NCT06682507
Locations
🇨🇳

The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Universal CAR-T Cell Therapy for Refractory Lupus Nephritis

Early Phase 1
Not yet recruiting
Conditions
Lupus Nephritis
Interventions
Biological: BCMA CART + CD19 CART
First Posted Date
2024-11-08
Last Posted Date
2024-11-08
Lead Sponsor
Bioray Laboratories
Target Recruit Count
10
Registration Number
NCT06681337

NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis

Phase 1
Not yet recruiting
Conditions
Refractory Systemic Lupus Erythematosus
Refractory Lupus Nephritis
Interventions
Biological: NK 010 or NK042
Drug: Rituximab
First Posted Date
2024-11-06
Last Posted Date
2024-11-06
Lead Sponsor
Guangdong Provincial People's Hospital
Target Recruit Count
18
Registration Number
NCT06676631

The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN)

Phase 1
Active, not recruiting
Conditions
Antineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis (AAGN)
Interventions
First Posted Date
2024-10-24
Last Posted Date
2024-10-24
Lead Sponsor
Renmin Hospital of Wuhan University
Target Recruit Count
15
Registration Number
NCT06656962
Locations
🇨🇳

Renmin hospital of Wuhan University, Wuhan, Hubei, China

Urinary Congophilia As an Indicator of Activity of Lupus Nephritis

Not yet recruiting
Conditions
Lupus Nephritis (LN)
First Posted Date
2024-10-23
Last Posted Date
2024-12-16
Lead Sponsor
Assiut University
Target Recruit Count
74
Registration Number
NCT06654024
Locations
🇪🇬

Assuit University ,Faculty of Medicine, Assute, Egypt

© Copyright 2025. All Rights Reserved by MedPath